Company Introduction:

Guangzhou Yonglikang Medical Consulting Services Co., Ltd. (referred to as "Yonglikang") was established in September 2021. It is a professional localized clinical trial site management organization (SMO) and a wholly-owned subsidiary of Guangzhou Haibote Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Haibote"). It is committed to providing one-stop professional clinical trial outsourcing management services for pharmaceutical enterprises, clinical trial institutions, researchers, and CROs.

Within just two years of its establishment, Yonglikang has established a professional CRC team of 150 people, all of whom have full-time medical, pharmaceutical, and nursing backgrounds and possess CRC qualifications. They can efficiently provide on-site management services for clinical trials. Our business covers clinical, real-world research, and instrument projects in phases I-IV, covering more than 32 cities across the country, including oncology, cardiovascular, endocrine, orthopedics, ophthalmology, respiratory, dermatology, and other fields.

Since its establishment, the professional team of Yonglikang has independently undertaken more than 80 clinical trial CRC dispatch projects for new drugs and medical devices, with experience in more than 5 multi center clinical trial projects. It has provided efficient, high-quality, and high pass clinical trial project on-site management services to more than 20 well-known pharmaceutical companies such as Hengrui Pharmaceutical, Zhengda Tianqing, Huahao Zhongtian, and Weineng Biotechnology, as well as more than 20 well-known CROs such as Taige Pharmaceutical, Haibote, and Novo Demei, as well as more than 100 hospitals such as Guang'anmen Hospital, Yunnan Provincial Institute of Pharmacy, and Guangdong Provincial Hospital of Traditional Chinese Medicine. The SMO services provided are at the forefront of the industry and meet international standards.

Relying on over 6000 clinical resources from its parent company, Haibote, Yonglikang has been selected as the preferred SMO for more than 50 clinical trial institutions, providing professional services to more than 1000 hospitals in China, including on-site CRC services, GCP training, and clinical research practical training services. It has established a good reputation and close cooperative relationships.